INmune Bio (INMB)

• Market cap: $34.8M
• 1 day: -1.5%
• 5 days: 0.77%
• 1 month: -9.03%
• 3 months: -31.41%
• 6 months: -33.5%
• Year to date: -14.94%
• 1 year: -83.71%
• 5 years: -91.15%
• 10 years: -83.6%
• Sector: Healthcare
• Industry: Biotechnology

About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Employees: 13